136 related articles for article (PubMed ID: 26324033)
21. Diagnostic utility of immunohistochemical panel in various thyroid pathologies.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Gardovskis J
Langenbecks Arch Surg; 2010 Sep; 395(7):885-91. PubMed ID: 20640858
[TBL] [Abstract][Full Text] [Related]
22. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536
[TBL] [Abstract][Full Text] [Related]
23. Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility.
Schmitt AC; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Aug; 118(4):196-202. PubMed ID: 20731005
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical Expression of HBME-1 and TROP-2 in Some Follicular-Derived Thyroid Lesions.
Abu-Seadah SS; Attiah SM; Ali MY; Shams El-Din M; El-Kholy MA
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2305-2311. PubMed ID: 37505760
[TBL] [Abstract][Full Text] [Related]
26. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D
Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194
[TBL] [Abstract][Full Text] [Related]
27. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
28. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF
Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
[TBL] [Abstract][Full Text] [Related]
29. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
30. Hybrid thyroid carcinoma with a coarse chromatin pattern and nuclear features of papillary thyroid carcinoma.
Mai KT; Bokhary R; Yazdi HM; Thomas J
Pathol Res Pract; 2002; 198(4):253-60. PubMed ID: 12049333
[TBL] [Abstract][Full Text] [Related]
31. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS
Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
[TBL] [Abstract][Full Text] [Related]
32. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.
Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S
Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236
[TBL] [Abstract][Full Text] [Related]
33. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.
de Micco C; Savchenko V; Giorgi R; Sebag F; Henry JF
Br J Cancer; 2008 Feb; 98(4):818-23. PubMed ID: 18212751
[TBL] [Abstract][Full Text] [Related]
34. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
35. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study.
Addati T; Achille G; Centrone M; Petroni S; Popescu O; Russo S; Grammatica L; Simone G
Cytopathology; 2015 Oct; 26(5):303-11. PubMed ID: 25164548
[TBL] [Abstract][Full Text] [Related]
36. HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma.
Ohta M; Ookoshi T; Naiki H; Imamura Y
Pathol Int; 2015 Mar; 65(3):119-25. PubMed ID: 25597783
[TBL] [Abstract][Full Text] [Related]
37. CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study.
Prasad ML; Pellegata NS; Kloos RT; Barbacioru C; Huang Y; de la Chapelle A
Thyroid; 2004 Mar; 14(3):169-75. PubMed ID: 15072698
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
40. Significance of AgNORs and ki-67 proliferative markers in differential diagnosis of thyroid lesions.
Aiad HA; Bashandy MA; Abdou AG; Zahran AA
Pathol Oncol Res; 2013 Apr; 19(2):167-75. PubMed ID: 23055017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
